Advancing therapeutic options for Erectile Dysfunction (ED)
The National Institutes of Health (NIH) Consensus Development Conference on Impotence defines male erectile dysfunction (ED) as the inability to achieve or maintain an erection sufficient for satisfactory sexual performance.
ED affects an estimated 12 million men between the ages of 40 and 79 in the United States.1 Prevalence increases with age and can be caused by a variety of factors, including medications (anti-hypertensives, histamine receptor antagonists); lifestyle (tobacco, alcohol use); diseases (diabetes, cardiovascular conditions, prostate cancer); and spinal cord injuries. Left untreated, ED can negatively impact relationships and self-esteem, causing feelings of embarrassment and guilt.
The number of men 40 to 79 years of age who have ED in the United States.1
In current practice, PDE5 inhibitors are the most commonly used treatment for ED.1 Guidelines from the American Urological Association (AUA) recommend offering PDE5 inhibitors as first-line therapy for ED unless the patient has contraindications to their use (e.g., concurrent organic nitrate therapy).2
Erectile Dysfunction Links
- Erectile Dysfunction, American Family Physician, Karl t. rew, MD, and Joel j. Heidelbaugh, MD - Volume 94, Number 10, November 15, 2016.
- American Urological Association Erectile Dysfunction Clinical Guidelines, Published 2005; Reviewed and Validity Confirmed 2011.